Lv1
58 积分 2025-03-17 加入
EARLY INTERVENTION PREVENTS DISEASE PROGRESSION IN ULCERATIVE COLITIS – A MULTICENTER RETROSPECTIVE STUDY
3天前
已完结
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
5天前
已完结
Hepcidin is a key mediator of anemia of inflammation in Crohn's disease
10天前
已完结
Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up
10天前
已完结
An evaluation of mirikizumab for the treatment of ulcerative colitis
10天前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
22天前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
22天前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
22天前
已完结
Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts
26天前
已关闭
Long-term Outcomes of Patients with Crohn’s Disease Treated with Risankizumab
26天前
已关闭
皖公网安备34019202002308
